An Activatable Prodrug for the Treatment of Metastatic Tumors
Publication Type:Journal Article
Source:Journal of the American Chemical Society, Volume 136, Number 39, p.13888-13894 (2014)
<p>Metastatic cancers have historically been difficult to treat. However, metastatic tumors have been found to have high levels of reactive oxygen species such as hydrogen peroxide (H2O2), supporting the hypothesis that a prodrug could be activated by intracellular H2O2 and lead to a potential antimetastatic therapy. In this study, prodrug 7 was designed to be activated by H2O2-mediated boronate oxidation, resulting in activation of the fluorophore for detection and release of the therapeutic agent, SN-38. Drug release from prodrug 7 was investigated by monitoring fluorescence after addition of H2O2 to the cancer cells. Prodrug 7 activated by H2O2, selectively inhibited tumor cell growth. Furthermore, intratracheally administered prodrug 7 showed effective antitumor activity in a mouse model of metastatic lung disease. Thus, this H2O2-responsive prodrug has therapeutic potential as a novel treatment for metastatic cancer via cellular imaging with fluorescence as well as selective release of the anticancer drug, SN-38.</p>
cited By (since 1996)0
Cite this Research Publication
Related Research Publications
- An activatable theranostic for targeted cancer therapy and imaging
- Potential use of drug loaded nano composite pectin scaffolds for the treatment of ovarian cancer.
- D-Aminoacid Oxidase-Fe2O3 Nanoparticle Complex Mediated Antitumor Activity in Swiss Albino Mice
- Thermo-responsive fibrinogen nanogels: a viable thermo-responsive drug delivery agent for breast cancer therapy?
- A polymer-protein core-shell nanomedicine for inhibiting cancer migration followed by photo-triggered killing